Klinefelter Syndrome
Common sex chromosome disorder in males (47,XXY) characterised by small testes, testosterone deficiency, gynaecomastia, and infertility.
Key Facts
- Klinefelter syndrome (47,XXY) is the most common sex chromosome aneuploidy in males, affecting 1 in 600 live male births
- 75% of cases remain undiagnosed; often identified during infertility investigation or incidentally
- Classic triad: small firm testes (<4mL), tall stature with eunuchoid proportions, and gynaecomastia
- Biochemistry: elevated FSH and LH (hypergonadotrophic hypogonadism), low testosterone, raised oestradiol
- Testosterone replacement is the mainstay of treatment (e.g., testosterone undecanoate 1000mg IM every 10-14 weeks)
- Azoospermia is present in >95%; micro-TESE with ICSI offers fertility potential in some patients
- Increased risk of breast cancer (20x), type 2 diabetes, osteoporosis, and venous thromboembolism
Overview
Key Facts
Klinefelter syndrome is a genetic condition in males caused by the presence of one or more extra X chromosomes. It is significantly underdiagnosed, with many cases not identified until adulthood during fertility investigations.
Epidemiology
- 1 in 600-660 live male births – one of the most common chromosomal abnormalities
- 75% of affected males are never diagnosed
- Increasing incidence of diagnosis due to prenatal screening (NIPT)
- Associated with advanced maternal age
Aetiology
- 47,XXY in ~80% of cases
- Mosaicism (46,XY/47,XXY) in ~10-20% – milder phenotype
- Higher-order aneuploidies (48,XXXY; 49,XXXXY) – more severe phenotype
- Additional X chromosome arises from non-disjunction during meiosis I (maternal) or meiosis II
Pathophysiology
- Extra X chromosome leads to primary testicular failure
- Seminiferous tubule dysgenesis → azoospermia/severe oligozoospermia
- Leydig cell dysfunction → reduced testosterone production
- Reduced testosterone + relatively increased oestradiol → gynaecomastia
- Hypergonadotrophic hypogonadism (elevated FSH/LH as pituitary tries to compensate)
- Testosterone deficiency during puberty → incomplete virilisation, eunuchoid habitus
Clinical Presentation
Pre-pubertal
- Often clinically silent
- May present with speech and language delay, learning difficulties
- Cryptorchidism in ~30%
- Tall stature may be evident from mid-childhood
Pubertal/Adolescent
- Delayed or incomplete puberty
- Small, firm testes (<4mL bilaterally) – pathognomonic
- Gynaecomastia (40-75%)
- Tall stature with disproportionately long legs (eunuchoid proportions: arm span > height)
- Sparse facial and body hair
- Reduced muscle mass
Adult
- Infertility (most common presenting complaint in adults)
- Erectile dysfunction, low libido
- Fatigue, mood disturbance, depression
- Metabolic syndrome features: central obesity, insulin resistance
- Osteoporosis/osteopenia
Red Flags
- Breast mass → increased breast cancer risk (20-50x general male population)
- Unilateral leg swelling → increased DVT/PE risk
- New-onset bone pain or fragility fracture → osteoporosis screening
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| Kallmann syndrome | Anosmia, hypogonadotrophic hypogonadism, normal karyotype | Smell test, GnRH stimulation, MRI pituitary |
| Constitutional delay of puberty | Family history, delayed bone age, eventual normal puberty | Bone age, karyotype |
| Testicular failure (other causes) | Normal karyotype, variable aetiology | Karyotype, testicular USS |
| Prolactinoma | Hypogonadism, visual field defects, galactorrhoea | Prolactin, MRI pituitary |
| Androgen insensitivity syndrome | 46,XY, female phenotype or undervirilisation | Karyotype, testosterone, DHT |
Diagnosis / Investigation
Bedside
- Testicular volume assessment (Prader orchidometer): typically <4mL
- Assess for gynaecomastia, body habitus, virilisation
- Height, arm span, BMI
Bloods
- Karyotype: diagnostic – 47,XXY or mosaic
- Testosterone (early morning): low or low-normal
- FSH: elevated (often markedly)
- LH: elevated
- Oestradiol: may be elevated (relative to testosterone)
- SHBG: variable
- Inhibin B: low (marker of Sertoli cell function)
- HbA1c/fasting glucose: screen for diabetes
- Lipid profile: metabolic risk assessment
- Bone profile: calcium, vitamin D
Imaging
- Testicular ultrasound: small, often heterogeneous testes
- DEXA scan: assess bone density
- Breast imaging (mammography/USS): if breast mass palpated
Special Tests
- Semen analysis: typically azoospermia (>95%)
- Bone age X-ray: may be normal or slightly delayed
- Echocardiography: consider if cardiovascular risk factors present (MVP in ~50%)
Management
Non-pharmacological
- Speech and language therapy in childhood if delays identified
- Educational support (specific learning difficulties in language-based tasks)
- Psychological support: counselling for diagnosis, body image, fertility concerns
- Lifestyle modification: exercise, weight management for metabolic risk
Pharmacological
- Testosterone replacement therapy (start at puberty or when diagnosed if hypogonadal):
- Testosterone undecanoate (Nebido) 1000mg IM every 10-14 weeks
- Testosterone enanthate/cypionate 250mg IM every 3-4 weeks
- Testogel 1% (50mg/day) transdermal
- Testosterone patches (may cause skin irritation)
- Monitor: testosterone levels, PSA, FBC (polycythaemia), liver function, lipids
- Calcium and vitamin D supplementation for bone health
- Bisphosphonates if osteoporosis confirmed on DEXA
Surgical/Interventional
- Mastectomy/breast reduction for significant gynaecomastia
- Micro-TESE (testicular sperm extraction) + ICSI: may retrieve sperm in up to 50% of patients
- Consider sperm cryopreservation in adolescence if any sperm present
Referral Criteria
- Paediatric/adult endocrinology for testosterone management
- Fertility clinic for family planning
- Genetics for counselling
- Breast clinic if breast abnormality detected
Prognosis
- Life expectancy reduced by approximately 2-5 years compared to general population
- Increased mortality from cardiovascular disease, diabetes, and cancer
- Breast cancer risk: 20-50 fold increased (lifetime risk ~3%)
- Osteoporosis develops in 25-48% without testosterone replacement
- With testosterone replacement, many symptoms are manageable and quality of life is good
- Fertility: 40-50% success with micro-TESE + ICSI in specialised centres
- Intellectual ability is generally normal; specific difficulties with language and executive function
Other Relevant Information
Klinefelter Variants
| Karyotype | Frequency | Phenotype |
|---|---|---|
| 47,XXY | 80% | Classic Klinefelter |
| 46,XY/47,XXY | 10-20% | Milder, may be fertile |
| 48,XXXY | Rare | More severe intellectual disability |
| 49,XXXXY | Very rare | Severe ID, skeletal abnormalities |
Monitoring on Testosterone Replacement
| Test | Frequency |
|---|---|
| Testosterone level (trough) | 3-6 monthly initially, then annual |
| FBC (haematocrit) | 3-6 monthly then annual |
| PSA | Annual (>40 years) |
| Lipid profile | Annual |
| DEXA scan | Every 2-3 years |
| HbA1c | Annual |